Shanghai OPM Biosciences Co., Ltd. (SHA:688293)
China · Delayed Price · Currency is CNY 52.64
-0.54 (-1.02%)
At close: Feb 13, 2026
Shanghai OPM Biosciences Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 352.45 | 296.78 | 242.69 | 294.27 | 212.68 | 124.97 |
Other Revenue | 0.47 | 0.47 | 0.43 | 0.1 | - | - |
| 352.91 | 297.24 | 243.12 | 294.37 | 212.68 | 124.97 | |
Revenue Growth (YoY) | 22.84% | 22.26% | -17.41% | 38.41% | 70.19% | 113.55% |
Cost of Revenue | 173.86 | 142.34 | 101.53 | 107.25 | 86 | 68.01 |
Gross Profit | 179.06 | 154.9 | 141.59 | 187.12 | 126.69 | 56.96 |
Selling, General & Admin | 92.61 | 105.94 | 74.47 | 60 | 50.96 | 29.69 |
Research & Development | 45.75 | 33.37 | 41.91 | 32.19 | 19.03 | 20.51 |
Other Operating Expenses | 6.44 | 2.21 | -0.23 | 1.17 | 0.78 | 0.17 |
Operating Expenses | 148.26 | 148.44 | 122.57 | 98.11 | 71.09 | 50.47 |
Operating Income | 30.8 | 6.46 | 19.02 | 89 | 55.6 | 6.49 |
Interest Expense | -2.81 | -3.12 | -3.23 | -4.98 | -4.79 | -2.45 |
Interest & Investment Income | 44.6 | 31.14 | 36.3 | 17.98 | 9.07 | 3.56 |
Currency Exchange Gain (Loss) | 2.4 | 2.4 | 0.87 | 2.24 | -0.24 | -0.53 |
Other Non Operating Income (Expenses) | -0.18 | -0.05 | -0.09 | -0.14 | -0.07 | -0.15 |
EBT Excluding Unusual Items | 74.81 | 36.84 | 52.89 | 104.09 | 59.57 | 6.91 |
Gain (Loss) on Sale of Investments | -1.54 | 4.63 | 1.53 | 1.67 | - | - |
Gain (Loss) on Sale of Assets | 0.01 | 0.09 | -0.02 | 0.29 | -0.02 | - |
Asset Writedown | -10.67 | -7.51 | - | - | - | -0 |
Other Unusual Items | 3.51 | 2.38 | 7.26 | 13.38 | 8.61 | 4.77 |
Pretax Income | 66.11 | 36.43 | 61.67 | 119.43 | 68.15 | 11.68 |
Income Tax Expense | 23.46 | 16.19 | 8.41 | 14.06 | 7.76 | - |
Earnings From Continuing Operations | 42.66 | 20.24 | 53.26 | 105.37 | 60.39 | 11.68 |
Minority Interest in Earnings | 0.59 | 0.82 | 0.78 | - | - | - |
Net Income | 43.24 | 21.05 | 54.04 | 105.37 | 60.39 | 11.68 |
Net Income to Common | 43.24 | 21.05 | 54.04 | 105.37 | 60.39 | 11.68 |
Net Income Growth | 13.53% | -61.04% | -48.72% | 74.47% | 416.87% | - |
Shares Outstanding (Basic) | 110 | 111 | 115 | 101 | 86 | 86 |
Shares Outstanding (Diluted) | 118 | 117 | 115 | 101 | 86 | 86 |
Shares Change (YoY) | 2.79% | 1.72% | 13.48% | 17.43% | 0.20% | - |
EPS (Basic) | 0.39 | 0.19 | 0.47 | 1.04 | 0.70 | 0.14 |
EPS (Diluted) | 0.37 | 0.18 | 0.47 | 1.04 | 0.70 | 0.14 |
EPS Growth | 10.45% | -61.70% | -54.81% | 48.57% | 415.84% | - |
Free Cash Flow | 21.21 | -51.61 | -19.59 | -35.34 | 8.64 | -33.04 |
Free Cash Flow Per Share | 0.18 | -0.44 | -0.17 | -0.35 | 0.10 | -0.38 |
Dividend Per Share | 0.200 | 0.420 | 0.440 | 0.429 | - | - |
Dividend Growth | -55.59% | -4.47% | 2.66% | - | - | - |
Gross Margin | 50.74% | 52.11% | 58.24% | 63.57% | 59.56% | 45.58% |
Operating Margin | 8.73% | 2.17% | 7.82% | 30.23% | 26.14% | 5.19% |
Profit Margin | 12.25% | 7.08% | 22.23% | 35.80% | 28.40% | 9.35% |
Free Cash Flow Margin | 6.01% | -17.36% | -8.06% | -12.01% | 4.06% | -26.44% |
EBITDA | 72.37 | 42.22 | 47.04 | 113.28 | 74.34 | 21.98 |
EBITDA Margin | 20.51% | 14.21% | 19.35% | 38.48% | 34.96% | 17.58% |
D&A For EBITDA | 41.57 | 35.76 | 28.02 | 24.28 | 18.74 | 15.49 |
EBIT | 30.8 | 6.46 | 19.02 | 89 | 55.6 | 6.49 |
EBIT Margin | 8.73% | 2.17% | 7.82% | 30.23% | 26.14% | 5.19% |
Effective Tax Rate | 35.48% | 44.45% | 13.63% | 11.78% | 11.39% | - |
Revenue as Reported | 352.91 | 297.24 | 243.12 | 294.37 | 212.68 | 124.97 |
Advertising Expenses | - | 2.08 | 2.29 | 1.34 | 0.73 | 0.23 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.